Yahoo
NasdaqGS - Delayed Quote USD

Krystal Biotech, Inc. (KRYS)

358.24 -13.23 (-3.56%)
At close: September 4 at 4:00:01 PM EDT
357.97 -0.27 (-0.08%)
After hours: September 4 at 7:55:12 PM EDT
Trade KRYS on Coinbase
Chart Range Bar
Loading chart for KRYS
  • Previous Close 371.47
  • Open 371.99
  • Bid 352.61 x 200
  • Ask 332.34 x 100
  • Day's Range 353.74 - 371.99
  • 52 Week Range 136.73 - 382.54
  • Volume 319,765
  • Avg. Volume 412,032
  • Market Cap (intraday) 10.603B
  • Beta (5Y Monthly) 0.54
  • PE Ratio (TTM) 44.84
  • EPS (TTM) 7.99
  • Earnings Date (est.) Nov 2, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 385.00

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

www.krystalbio.com

295

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

KRYS
45.31%
S&P 500 (^GSPC)
12.75%

1-Year Return

KRYS
139.23%
S&P 500 (^GSPC)
18.71%

3-Year Return

KRYS
183.75%
S&P 500 (^GSPC)
70.93%

5-Year Return

KRYS
511.64%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 119.22M
Earnings 54.77M
Profit Margin 45.94%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
20M
40M
60M
80M
100M
50.0%
60.0%
70.0%
80.0%

Analyst Insights

View More

Analyst Price Targets

284.00 Low
385.00 Average
358.24 Current
474.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/14/2026
Analyst RBC Capital
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 400

Statistics

View More

Valuation Measures

Annual
As of 9/3/2026
  • Market Cap

    11.00B

  • Enterprise Value

    10.16B

  • Trailing P/E

    46.55

  • Forward P/E

    51.02

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    25.58

  • Price/Book (mrq)

    8.09

  • Enterprise Value/Revenue

    23.06

  • Enterprise Value/EBITDA

    49.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    54.82%

  • Return on Assets (ttm)

    9.37%

  • Return on Equity (ttm)

    20.12%

  • Revenue (ttm)

    440.48M

  • Net Income Avi to Common (ttm)

    241.46M

  • Diluted EPS (ttm)

    7.99

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    845.63M

  • Total Debt/Equity (mrq)

    0.65%

  • Levered Free Cash Flow (ttm)

    151.74M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

358.24 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Raising target price to $400.00

    KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $400.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Raising target price to $392.00

    KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $392.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Raising target price to $366.00

    KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $366.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Daily – Vickers Top Buyers & Sellers for 08/17/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: